Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Palo Alto Medical Foundation
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: June 1989
History of Changes
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
Drug : Pyrimethamine
Drug : Clindamycin
Primary Purpose: Treatment
|Official Title:||Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients with the following conditions are excluded:
- Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002064
Locations Show More
|United States, California|
|Palo Alto Med Foundation|
|Palo Alto, California, United States, 94301|
Sponsors and CollaboratorsPalo Alto Medical Foundation
|Responsible Party:||Palo Alto Medical Foundation|
|ClinicalTrials.gov Identifier:||NCT00002064 History of Changes|
|Other Study ID Numbers:||021A|
|Study First Received:||November 2, 1999|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:Sulfonamides
AIDS-Related Opportunistic Infections
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 20, 2017
This information is provided by ClinicalTrials.gov.